274 related articles for article (PubMed ID: 34944577)
1. Animal Models in Bladder Cancer.
Constantin T; Păvălean M; Bucur Ș; Constantin MM; Nicolescu AC; Pacu I; Mădan V
Biomedicines; 2021 Nov; 9(12):. PubMed ID: 34944577
[TBL] [Abstract][Full Text] [Related]
2. Current animal models of bladder cancer: Awareness of translatability (Review).
Ding J; Xu D; Pan C; Ye M; Kang J; Bai Q; Qi J
Exp Ther Med; 2014 Sep; 8(3):691-699. PubMed ID: 25120584
[TBL] [Abstract][Full Text] [Related]
3. The N-butyl-N-4-hydroxybutyl Nitrosamine Mouse Urinary Bladder Cancer Model.
Oliveira PA; Vasconcelos-Nóbrega C; Gil da Costa RM; Arantes-Rodrigues R
Methods Mol Biol; 2018; 1655():155-167. PubMed ID: 28889385
[TBL] [Abstract][Full Text] [Related]
4. Insights from animal models of bladder cancer: recent advances, challenges, and opportunities.
John BA; Said N
Oncotarget; 2017 Aug; 8(34):57766-57781. PubMed ID: 28915710
[TBL] [Abstract][Full Text] [Related]
5. Tumor establishment features of orthotopic murine bladder cancer models.
Lee JS; Bae MH; Choi SH; Lee SH; Cho YS; Park HJ; Kwon CH; Joo KJ
Korean J Urol; 2012 Jun; 53(6):396-400. PubMed ID: 22741047
[TBL] [Abstract][Full Text] [Related]
6. Orthotopic Mouse Models of Urothelial Cancer.
Jäger W; Moskalev I; Raven P; Goriki A; Bidnur S; Black PC
Methods Mol Biol; 2018; 1655():177-197. PubMed ID: 28889387
[TBL] [Abstract][Full Text] [Related]
7. A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypes.
Wang L; Smith BA; Balanis NG; Tsai BL; Nguyen K; Cheng MW; Obusan MB; Esedebe FN; Patel SJ; Zhang H; Clark PM; Sisk AE; Said JW; Huang J; Graeber TG; Witte ON; Chin AI; Park JW
Proc Natl Acad Sci U S A; 2020 Jan; 117(1):563-572. PubMed ID: 31871155
[TBL] [Abstract][Full Text] [Related]
8. Systematic Review: Characteristics and Preclinical Uses of Bladder Cancer Cell Lines.
Zuiverloon TCM; de Jong FC; Costello JC; Theodorescu D
Bladder Cancer; 2018 Apr; 4(2):169-183. PubMed ID: 29732388
[TBL] [Abstract][Full Text] [Related]
9. Urothelial carcinoma of the bladder and the upper tract: disparate twins.
Green DA; Rink M; Xylinas E; Matin SF; Stenzl A; Roupret M; Karakiewicz PI; Scherr DS; Shariat SF
J Urol; 2013 Apr; 189(4):1214-21. PubMed ID: 23023150
[TBL] [Abstract][Full Text] [Related]
10. The anti-tumor effect of intravesical administration of normal urothelial cells on bladder cancer.
Huang CP; Chen CC; Shyr CR
Cytotherapy; 2017 Oct; 19(10):1233-1245. PubMed ID: 28818454
[TBL] [Abstract][Full Text] [Related]
11. The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma.
Vanden Borre P; McFadden DG; Gunda V; Sadow PM; Varmeh S; Bernasconi M; Jacks T; Parangi S
Thyroid; 2014 Apr; 24(4):705-14. PubMed ID: 24295207
[TBL] [Abstract][Full Text] [Related]
12. Mouse orthotopic models for bladder cancer research.
Chan E; Patel A; Heston W; Larchian W
BJU Int; 2009 Nov; 104(9):1286-91. PubMed ID: 19388981
[TBL] [Abstract][Full Text] [Related]
13. Pathological guidelines for orthotopic urinary diversion in women with bladder cancer: a review of the literature.
Stein JP; Penson DF; Wu SD; Skinner DG
J Urol; 2007 Sep; 178(3 Pt 1):756-60. PubMed ID: 17631333
[TBL] [Abstract][Full Text] [Related]
14. An orthotopic xenograft model for high-risk non-muscle invasive bladder cancer in mice: influence of mouse strain, tumor cell count, dwell time and bladder pretreatment.
Huebner D; Rieger C; Bergmann R; Ullrich M; Meister S; Toma M; Wiedemuth R; Temme A; Novotny V; Wirth MP; Bachmann M; Pietzsch J; Fuessel S
BMC Cancer; 2017 Nov; 17(1):790. PubMed ID: 29169339
[TBL] [Abstract][Full Text] [Related]
15. Naturally-Occurring Invasive Urothelial Carcinoma in Dogs, a Unique Model to Drive Advances in Managing Muscle Invasive Bladder Cancer in Humans.
Knapp DW; Dhawan D; Ramos-Vara JA; Ratliff TL; Cresswell GM; Utturkar S; Sommer BC; Fulkerson CM; Hahn NM
Front Oncol; 2019; 9():1493. PubMed ID: 32039002
[TBL] [Abstract][Full Text] [Related]
16. Histopathological characterization of a syngeneic orthotopic murine bladder cancer model.
Chade DC; Andrade PM; Borra RC; Leite KR; Andrade E; Villanova FE; Srougi M
Int Braz J Urol; 2008; 34(2):220-6; discussion 226-9. PubMed ID: 18462521
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of human bladder cancer growth by a suicide gene delivered by JC polyomavirus virus-like particles in a mouse model.
Fang CY; Tsai YD; Lin MC; Wang M; Chen PL; Chao CN; Huang YL; Chang D; Shen CH
J Urol; 2015 Jun; 193(6):2100-6. PubMed ID: 25623749
[TBL] [Abstract][Full Text] [Related]
18. Use of prostate specific antigen to measure bladder tumor growth in a mouse orthotopic model.
Luo Y; Chen X; O'donnell MA
J Urol; 2004 Dec; 172(6 Pt 1):2414-20. PubMed ID: 15538283
[TBL] [Abstract][Full Text] [Related]
19. Real-time cancer cell tracking by bioluminescence in a preclinical model of human bladder cancer growth and metastasis.
van der Horst G; van Asten JJ; Figdor A; van den Hoogen C; Cheung H; Bevers RF; Pelger RC; van der Pluijm G
Eur Urol; 2011 Aug; 60(2):337-43. PubMed ID: 21616583
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts.
Vallo S; Michaelis M; Gust KM; Black PC; Rothweiler F; Kvasnicka HM; Blaheta RA; Brandt MP; Wezel F; Haferkamp A; Cinatl J
BMC Res Notes; 2016 Sep; 9(1):454. PubMed ID: 27677700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
